THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker - Takeaways - MDSpire

THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker

  • By

  • Alain Chebly

  • Edith Chevret

  • July 17, 2026

Share

  • 1

    THOR methylation is a paradoxical epigenetic mechanism that increases TERT expression across various cancers.

  • 2

    Unlike classical promoter methylation, THOR hypermethylation is associated with increased TERT transcription.

  • 3

    THOR methylation is prevalent in tumors lacking TERT promoter mutations and correlates with aggressive clinical behavior.

  • 4

    In hematological malignancies, THOR methylation may be the primary mechanism of telomerase activation.

  • 5

    THOR methylation represents a significant but singular aspect of the complex regulation of telomerase in cancer.

Original Source(s)

THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker

  • by Alain Chebly, Edith Chevret

  • July 17, 2026

Related Content

Proteomics and transcriptomics reveal molecular subtypes and biomarkers of advanced cutaneous T-cell lymphoma

Ten reasons why acute respiratory failure is different in the immunocompromised host

Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non–small cell lung cancer: the RECAPC multicenter registry